Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study

Published:2014-01-01 Issue:1 Volume:39 Page:40-49
ISSN:1180-4882
Container-title:Journal of Psychiatry & Neuroscience
language:
Short-container-title:J Psychiatry Neurosci

Author:

Bakish David,Bose Anjana,Gommoll Carl,Chen Changzheng,Nunez Rene,Greenberg William,Liebowitz Michael,Khan Arif

Publisher

CMA Joule Inc.

Subject

Pharmacology (medical),Biological Psychiatry,Psychiatry and Mental health

Link

https://jpn.ca/wp-content/uploads/2014/04/39-1-40.pdf

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Differential Outcomes of Placebo Treatment Across 9 Psychiatric Disorders;JAMA Psychiatry;2024-08-01

2. Safety and Efficacy of Levomilnacipran Extended Release in Pediatric Patients Aged 7–17 Years with Major Depressive Disorder: Results of Two Phase 3, Randomized, Double-Blind Studies;Journal of Child and Adolescent Psychopharmacology;2024-06-01

3. Practical pathway for the management of depression in the workplace: a Canadian perspective;Frontiers in Psychiatry;2023-09-05

4. Recent Developments in Pharmacotherapy of Depression: Bench to Bedside;Journal of Personalized Medicine;2023-04-29

5. The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de‐risk trial programmes of novel agents;World Psychiatry;2023-01-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP